Theratechnologies (TSX:TH) announced that it has received feedback from the FDA regarding the timeline to review tesamorelin’s New Drug Application for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The FDA has indicated that the review is progressing well. The Company now expects to have an official response in the fourth quarter of 2010. Theratechnologies and the Agency continue the positive and constructive dialogue regarding the regulatory process for tesamorelin.
The coming months will be entertaining in the obesity market with 3 companies fighting to get FDA approval.
About the company: Theratechnologies (TSE:TH), (PINK:THTCF) is a Canadian biopharmaceutical company that discovers and develops innovative therapeutic products. The Company targets unmet medical needs in financially attractive specialty markets where it can retain all or part of the commercial rights to its products. Its most advanced compound, tesamorelin, is an analogue of the human growth [...]
Invo Bioscience Inc. (OTCBB: IVOB) World Health Organization statistics imply that infertility and sterility will be the third most serious diseases in the 21st century after cancer and cardiovascular diseases, according to a Life Times report. InvoBioscience is engaged in providing its InvoCell technology to help infertile couples have a baby. It has one principal [...]
Biotechs are fascinating. They have such great promise, yet very few of them actually turn those promises into money — Advaxis, Inc. (OTCBB: ADXS) is a beginner in the biotech oncology world, but has recently shown some reason to think they stand out from the pack. ADXS might be one of these hidden gems, following [...]
